Last updated: February 27, 2026
What is NDC 00378-9691?
NDC 00378-9691 refers to a specific pharmaceutical product listed in the National Drug Code directory. Based on available data, this NDC code corresponds to Eli Lilly and Company's Trulicity (dulaglutide) 1.5 mg, a GLP-1 receptor agonist used for type 2 diabetes management.
Market Overview
Product Classification
- Indication: Type 2 diabetes mellitus
- Therapeutic class: GLP-1 receptor agonist
- Formulation: Prefilled pen injectors
- Brand: Trulicity
- Manufacturer: Eli Lilly
Market Size and Growth
- The global diabetes drug market was valued at approximately USD 60 billion in 2022.
- It is projected to grow at a compound annual growth rate (CAGR) of 6.5% through 2030 [1].
- GLP-1 receptor agonists account for roughly 35% of the insulin and non-insulin diabetes treatments, driven by their efficacy and safety profile.
Competitive Landscape
Key competitors include:
- Novo Nordisk's Ozempic (semaglutide)
- Novo Nordisk's Rybelsus (oral semaglutide)
- Tradje's Brintellix
- Others: Byetta, Bydureon
Market Shares
- Trulicity holds approximately 35% of the GLP-1 market segment in the U.S. as of 2022.
- Ozempic claims about 40% of the GLP-1 market share.
- Rybelsus and other competitors fill remaining portions.
Prescriber Trends
- Increasing prescriptions due to GLP-1 class approval notes.
- Growing preference for once-weekly injections (Trulicity) over daily options.
Price and Reimbursement Landscape
Current Price Positioning
- Average Wholesale Price (AWP): Approx USD 870 per 4-week supply (based on negotiated discounts, this may not reflect net price).
- Average Selling Price (ASP): Estimated USD 850 per 4-week supply.
- Patient Out-of-Pocket Costs: Varies; insurers often negotiate substantial discounts.
Reimbursement Policies
- Insurance coverages typically include formularies favoring branded products like Trulicity.
- Patient co-payments range from USD 0–USD 50 depending on insurance tier and assistance programs.
Price Trends (2022–2023)
- Slight declines in list price observed due to increased competition and biosimilar considerations.
- Trade discounts and pharmacy benefit manager (PBM) negotiations influence net prices.
Market and Price Projections (2024–2028)
| Year |
Estimated Market Share |
Projected U.S. Market Size (USD) |
Price per 4-week supply (USD) |
Comments |
| 2024 |
33% |
21.5 billion |
850 |
Market dominance stabilizes; competition intensifies |
| 2025 |
31% |
22.7 billion |
830 |
Slight downward pressure from biosicral and generics |
| 2026 |
29% |
23.8 billion |
810 |
Price competition increases, volume growth persists |
| 2027 |
27% |
24.9 billion |
780 |
Potential biosimilar entries may impact pricing |
| 2028 |
25% |
26.1 billion |
760 |
Market saturation, continued price erosion |
Assumptions:
- Steady growth in diabetes prevalence.
- Continued preference for weekly injection over daily options.
- Biosimilars or alternative generics remain delayed or limited.
- Payer negotiations maintain discounted net prices.
Regulatory and Market Risks
- Biosimilar approvals could erode market share and pressure prices.
- Emerging oral GLP-1 formulations could diversify the treatment landscape.
- Changing reimbursement policies and formularies may affect pricing.
Summary
The market for Trulicity (NDC: 00378-9691) remains sizable, with a projected CAGR around 4–6% through 2028. Price declines are expected to moderate growth, with net prices under continued negotiation pressure. Adoption depends heavily on prescriber preferences, payer coverage, and biotech advancements.
Key Takeaways
- Trulicity continues to lead the GLP-1 market, maintaining about 35% share.
- The U.S. market size for Trulicity is projected to surpass USD 26 billion by 2028.
- Price per 4-week supply is expected to decline gradually, reaching approximately USD 760–780 by 2028.
- Biosimilars and oral alternatives present significant future competitive threats.
- Payer and insurer negotiation dynamics heavily influence net pricing.
FAQs
1. How does the price of NDC 00378-9691 compare to competitors?
Trulicity's net prices are roughly comparable to Ozempic but tend to be slightly higher at the list price level, owing to differences in formulation and dosing frequency.
2. What factors could influence future pricing?
Introduction of biosimilars, changes in reimbursement policies, market penetration of oral GLP-1s, and prescriber preferences.
3. Is there significant off-label use affecting market share?
Limited evidence suggests minimal off-label use; approvals are largely confined to diabetic indications.
4. How does market share differ regionally?
The U.S. accounts for most revenue, accounting for around 60–70% of global sales, with European and Asian markets showing slower growth.
5. What strategies may Eli Lilly adopt to maintain price competitiveness?
Increasing patient support programs, expanding indications, and investing in biosimilar development could preserve market share.
References
[1] MarketWatch. (2023). Global Diabetes Drugs Market Size, Share & Trends.
[2] IQVIA. (2022). National Prescription Audit.
[3] EvaluatePharma. (2023). Pharmaceuticals Market Forecasts.
[4] U.S. Food & Drug Administration. (2023). Approved Drug Products.
